- Home
- KYMR vs THG Comparison
KYMR vs THG Comparison
Compare KYMR & THG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KYMR | THG |
|---|---|---|
| Founded | 2015 | 1852 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.3B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | KYMR | THG |
|---|---|---|
| Price | $80.62 | $173.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 6 |
| Target Price | $107.72 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 627.8K | 198.8K |
| Earning Date | 05-18-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 2.17% |
| EPS Growth | N/A | ★ 55.21 |
| EPS | N/A | ★ 18.16 |
| Revenue | $39,211,000.00 | ★ $6,594,400,000.00 |
| Revenue This Year | $16.05 | $3.04 |
| Revenue Next Year | $4.79 | $4.24 |
| P/E Ratio | ★ N/A | $9.64 |
| Revenue Growth | N/A | ★ 5.72 |
| 52 Week Low | $19.45 | $147.76 |
| 52 Week High | $103.00 | $188.18 |
Technical Indicators
Market Signals| Indicator | KYMR | THG |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 45.03 |
| Support Level | $77.78 | $173.68 |
| Resistance Level | $95.90 | $180.14 |
| Average True Range (ATR) | 4.42 | 3.55 |
| MACD | -1.27 | -0.51 |
| Stochastic Oscillator | 23.04 | 24.50 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About THG Hanover Insurance Group Inc
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business through Hanover Insurance, Citizens and other THG subsidiaries. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.